Dr. Daniel A. Erlanson is the co-founder and President of Carmot Therapeutics, Inc. Using a proprietary technology called Chemotype Evolution, Carmot is addressing unmet chemical needs in drug discovery to tackle challenging therapeutic targets. Prior to Carmot, Dr. Erlanson spent a decade developing fragment-based drug discovery technologies and leading medicinal chemistry efforts in oncology and in metabolic and inflammatory diseases at Sunesis Pharmaceuticals, which he joined at the company’s inception. Before Sunesis, he was an NIH postdoctoral fellow with James A. Wells at Genentech. Dr. Erlanson earned his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine and his BA in chemistry from Carleton College. As well as co-editing the first book on fragment-based drug discovery, Dr. Erlanson is an inventor on more than a dozen issued patents and published patent applications, an author of more than thirty scientific publications, and has presented at more than fifty national and international conferences. He is also editor of a blog devoted to fragment-based drug discovery, Practical Fragments.